Key result
Percutaneous left atrial appendage occlusion is a viable option for stroke prevention in patients with atrial fibrillation who have contraindications to anticoagulation therapy.
Why the study?
Despite oral anticoagulation options for AF thromboembolic risk, limitations persist, while significant changes to the commissioning and delivery of percutaneous left atrial appendage occlusion have occurred in the UK.
This review describes the use of percutaneous left atrial appendage occlusion in the UK and discusses the challenges in commissioning and delivery of this service.
AF is associated with an increased risk of thromboembolic events, which is usually managed with oral anticoagulation therapy. However, despite a broad range of anticoagulant options and improved uptake in anticoagulation over the past decade, there are some limitations to this approach. Percutaneous left atrial appendage occlusion has been shown to be an effective alternative in this setting, and population data suggest a clear demand for this procedure. Over the past decade, several important changes to the commissioning and delivery of this service have occurred in the UK. In this article, the authors describe the use of percutaneous left atrial appendage occlusion in the UK and discuss the challenges that lie ahead.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2020) conducted a review in Atrial Fibrillation. Percutaneous Left Atrial Appendage Occlusion vs. Oral anticoagulation was evaluated. Percutaneous left atrial appendage occlusion is a viable option for stroke prevention in patients with atrial fibrillation who have contraindications to anticoagulation therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: